AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16880785 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 37
Study 16880785 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised patients with stable disease
Number of subjects: 37
Study 16880785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 37
Study 15701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified, heated gas
Number of subjects: 90
Study 15701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry, heated gas
Number of subjects: 90
Study 15701188 — intervention group
Group type: COMPARATOR
Intervention: Standard dry, cold gas (control group)
Number of subjects: 90
Study 11340825 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teaching group (1 hour/week for 10 weeks)
Number of subjects: 36
Study 11340825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive teaching group (2 hours daily for 5 days)
Number of subjects: 36
Study 11340825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 15562667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost assessments in the management of variceal hemorrhage
Number of subjects: 0
Study 7957152 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA infusion (260 mg x kg‐1 x h‐1 for 70 min)
Number of subjects: 6
Study 7957152 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 3357367 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive upright tilt (1 minute at 15 degrees, 2 minutes at 45 degrees, 7 minutes at 85 degrees)
Number of subjects: 35
Study 3357367 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration before passive upright tilt
Number of subjects: 35
Study 29988969 — intervention group
Group type: EXPERIMENTAL
Intervention: internet‐based cognitive‐behavioural therapy (iCBT)
Number of subjects: 70
Study 29988969 — intervention group
Group type: COMPARATOR
Intervention: attention control
Number of subjects: 70
Study 28161309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 79
Study 26032206 — intervention group
Group type: EXPERIMENTAL
Intervention: vitD3 supplementation (7,000 IU/day)
Number of subjects: 56
Study 26032206 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 23085729 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Number of subjects: 470
Study 23085729 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS indication
Number of subjects: 470
Study 23085729 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without ONS)
Number of subjects: 470
Study 21558574 — intervention group
Group type: EXPERIMENTAL
Intervention: GliSODin extract (500 mg, 2 capsules once daily for 6 weeks)
Number of subjects: 19
Study 21558574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19365716 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-week social competence and social skills group intervention program
Number of subjects: 18
Study 19365716 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18
Study 17011760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (prostaglandin E(1) analogue) administered during operation
Number of subjects: 42
Study 17011760 — intervention group
Group type: COMPARATOR
Intervention: Control group without alprostadil
Number of subjects: 42
Study 15327935 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal tactile or visual stimuli
Number of subjects: 16
Study 15327935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal (tactile and visual) stimuli
Number of subjects: 16
Study 15327935 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study 11550161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine oral rinse, 15 mL for 2 minutes, 4-8 times daily before and during RT, and for 2 weeks after completion of RT.
Number of subjects: 145
Study 11550161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 11550161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine oral rinse
Number of subjects: 145
Study 11550161 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated RT doses (> or = 220 cGy/day)
Number of subjects: 145
Study 11550161 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine and placebo
Number of subjects: 145
Study 9248981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine gene expression detection using RT-PCR in severely infected patients
Number of subjects: 6
Study 9248981 — intervention group
Group type: COMPARATOR
Intervention: Cytokine gene expression detection using RT-PCR in healthy volunteers
Number of subjects: 6
Study 8271169 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 60
Study 8271169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 60
Study 8271169 — intervention group
Group type: COMPARATOR
Intervention: BSS (Balanced Salt Solution)
Number of subjects: 60
Study 3135572 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms every second day up to day 28, subcutaneous injection)
Number of subjects: 91
Study 3135572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 30244430 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular common elements approach to evidence-based practices (EBPs) training
Number of subjects: 80
Study 30244430 — intervention group
Group type: COMPARATOR
Intervention: Non-modular evidence-based practices (EBPs) training
Number of subjects: 80
Study 28774663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track insertion (≤3 days)
Number of subjects: 108
Study 28774663 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion (2-4 weeks)
Number of subjects: 108
Study 25911881 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC (Hepatic artery infusion chemotherapy) - 5‐FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1, Gemcitabine 1000 mg/m2 on day 1 and 8, starting 3 weeks after operation with intervals of 4 weeks.
Number of subjects: 85
Study 25911881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 85
Study 23357657 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral activation combined with acceptance and commitment therapy (ACT) for 8 weeks
Number of subjects: 80
Study 23357657 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 80
Study 21282809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) added to general exercise training
Number of subjects: 32
Study 21282809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 32
Study 21282809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle endurance training
Number of subjects: 32
Study 17635971 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EDBP)
Number of subjects: 42
Study 17635971 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 42
Study 16476809 — intervention group
Group type: EXPERIMENTAL
Intervention: etilevodopa-carbidopa
Number of subjects: 327
Study 16476809 — intervention group
Group type: COMPARATOR
Intervention: levodopa-carbidopa
Number of subjects: 327
Study 15226212 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (PHT)
Number of subjects: 423
Study 15226212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 11789166 — intervention group
Group type: EXPERIMENTAL
Intervention: Chanbei Kechuanping (CBKCP)
Number of subjects: 96
Study 11789166 — intervention group
Group type: COMPARATOR
Intervention: Guilong Kechuanning (Control)
Number of subjects: 96
Study 8697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 mg.kg‐1
Number of subjects: 75
Study 8697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1 mg.kg‐1
Number of subjects: 75
Study 8697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg.kg‐1
Number of subjects: 75
Study 8697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg.kg‐1
Number of subjects: 75
Study 8697552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Edrophonium 0.0 mg.kg‐1)
Number of subjects: 75
Study 2003848 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication communication skills program
Number of subjects: 0
Study 2003848 — intervention group
Group type: COMPARATOR
Intervention: Medication education program
Number of subjects: 0
Study 6224928 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation and cognitive imagery treatment
Number of subjects: 30
Study 6224928 — intervention group
Group type: COMPARATOR
Intervention: Attention-comparison group
Number of subjects: 30
Study 6224928 — intervention group
Group type: COMPARATOR
Intervention: Medical control group
Number of subjects: 30
Study 31769729 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with primary care providers
Number of subjects: 11
Study 30377381 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT (30 hours)
Number of subjects: 45
Study 30377381 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 45
Study 28982774 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg plus fluticasone propionate 500 μg
Number of subjects: 60
Study 28982774 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 60
Study 26537393 — intervention group
Group type: EXPERIMENTAL
Intervention: Live demonstration (group A)
Number of subjects: 49
Study 26537393 — intervention group
Group type: COMPARATOR
Intervention: Procedural video (group B)
Number of subjects: 49
Study 23653047 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole, administered twice daily orally
Number of subjects: 10
Study 23653047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole
Number of subjects: 10
Study 23653047 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 10
Study 23653047 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10
Study 21393310 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm (169 babies) - attended workshops and promoted implementation of research evidence
Number of subjects: 180
Study 21393310 — intervention group
Group type: COMPARATOR
Intervention: Control arm (186 babies) - dissemination of research report and information
Number of subjects: 180
Study 19375681 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units IA-BoNT/A + lidocaine
Number of subjects: 43
Study 19375681 — intervention group
Group type: COMPARATOR
Intervention: IA-saline + lidocaine
Number of subjects: 43
Study 17905167 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 312
Study 17905167 — intervention group
Group type: COMPARATOR
Intervention: Vocational services
Number of subjects: 312
Study 17905167 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312
Study 15471151 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11410822 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 51
Study 11410822 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 51
Study 11410822 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance or regain
Number of subjects: 51
Study 11410822 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 51
Study 9757157 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled zidovudine regimen
Number of subjects: 20
Study 9757157 — intervention group
Group type: COMPARATOR
Intervention: Standard fixed-dose zidovudine (500 mg/day)
Number of subjects: 20
Study 7832680 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-80 amalgam alloy
Number of subjects: 301
Study 7832680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lojic+ amalgam alloy
Number of subjects: 301
Study 7832680 — intervention group
Group type: EXPERIMENTAL
Intervention: Permite C amalgam alloy
Number of subjects: 301
Study 7832680 — intervention group
Group type: COMPARATOR
Intervention: Dispersalloy, Valiant PhD, Lojic N
Number of subjects: 301
Study 3072961 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Survey Questionnaire (HSQ)
Number of subjects: 4203
Study 31658212 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Setting and Implementation Planning (GSIP) intervention
Number of subjects: 20
Study 31658212 — intervention group
Group type: COMPARATOR
Intervention: Passive control arm
Number of subjects: 20
Study 28506013 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized equipment-free exercise program (delivered by qualified fitness instructors)
Number of subjects: 92
Study 28506013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 92
Study 25033106 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management without stents (thrombectomy to restore TIMI 3 flow)
Number of subjects: 101
Study 23636098 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion over 30 minutes
Number of subjects: 43
Study 23636098 — intervention group
Group type: COMPARATOR
Intervention: Platelet transfusion over 120 minutes
Number of subjects: 43
Study 21562125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Number of subjects: 282
Study 21562125 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo every 4 hours for up to 10 days
Number of subjects: 282
Study 21562125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg)
Number of subjects: 282
Study 21562125 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 282
Study 19484320 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) consultation
Number of subjects: 26
Study 19484320 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) consultation
Number of subjects: 26
Study 16500364 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of clomiphene citrate alone (group A, n = 65)
Number of subjects: 125
Study 16500364 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of clomiphene citrate plus hCG (group B, n = 60)
Number of subjects: 125
Study 12670067 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect adhesive composite configurations with and without adhesive fiber posts
Number of subjects: 6
Study 12670067 — intervention group
Group type: COMPARATOR
Intervention: Adhesive composite onlays on 'vital' teeth (control)
Number of subjects: 6
Study 12879121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 12879121 — intervention group
Group type: COMPARATOR
Intervention: Standard NSAIDs
Number of subjects: 0
Study 12879121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8615729 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine
Number of subjects: 92
Study 8615729 — intervention group
Group type: COMPARATOR
Intervention: IM morphine
Number of subjects: 92
Study 8615729 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ketorolac
Number of subjects: 92
Study 1292340 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 22
Study 6537870 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein (Supro‐620)
Number of subjects: 24
Study 6537870 — intervention group
Group type: COMPARATOR
Intervention: Egg protein
Number of subjects: 24
Study 6537870 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein with 1.6% L‐methionine supplementation
Number of subjects: 24
Study 6537870 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein with 1.1% L‐methionine supplementation
Number of subjects: 24
Study 6537870 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented egg protein
Number of subjects: 24
Study 6537870 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein with methionine supplementation
Number of subjects: 24
Study 31221620 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening (annual MRI and clinical breast examination plus biennial mammography)
Number of subjects: 1355
Study 31221620 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 1355
Study 31221620 — intervention group
Group type: COMPARATOR
Intervention: Mammography screening
Number of subjects: 1355
Study 30459247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Number of subjects: 3207
Study 30459247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3207
Study 26937646 — intervention group
Group type: EXPERIMENTAL
Intervention: CartiJoint Forte (two tablets daily for 8 weeks)
Number of subjects: 53
Study 26937646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24065463 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a high-dose (1×10(13) DNase-resistant particles)
Number of subjects: 39
Study 24065463 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a low-dose (6×10(11) DNase-resistant particles)
Number of subjects: 39
Study 24065463 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a mid-dose (3×10(12) DNase-resistant particles)
Number of subjects: 39
Study 24065463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22520658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic in primary care (PCC)
Number of subjects: 76
Study 22520658 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based childhood obesity clinic (BRHC)
Number of subjects: 76
Study 22520658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trial arms (PCC and BRHC)
Number of subjects: 76
Study 19810664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical simulation in nursing education, replacing some early-term clinical placement hours with simulated clinical experience.
Number of subjects: 54
Study 19810664 — intervention group
Group type: COMPARATOR
Intervention: Clinical control group with all normally scheduled clinical hours.
Number of subjects: 54
Study 18480923 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB plus antihistamine
Number of subjects: 81
Study 18480923 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine (control)
Number of subjects: 81
Study 15737948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Number of subjects: 24
Study 15737948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15737948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 24
Study 15737948 — intervention group
Group type: COMPARATOR
Intervention: No CVVH
Number of subjects: 24
Study 12531659 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and Kirschner wire fixation
Number of subjects: 32
Study 12531659 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and lag screw fixation
Number of subjects: 32
Study 9440408 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises in the rehabilitation group
Number of subjects: 81
Study 9440408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study 9440408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 8531610 — intervention group
Group type: EXPERIMENTAL
Intervention: DIET/STTI
Number of subjects: 4
Study 8531610 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 4
Study 8531610 — intervention group
Group type: EXPERIMENTAL
Intervention: STTI
Number of subjects: 4
Study 2142271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of sterile water
Number of subjects: 45
Study 2142271 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injections of isotonic saline (placebo)
Number of subjects: 45
Study 2142271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 699486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg orally)
Number of subjects: 0
Study 699486 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study 31930845 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract (OLE)
Number of subjects: 60
Study 31930845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28865430 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic training intervention
Number of subjects: 88
Study 28865430 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional training
Number of subjects: 88
Study 26686681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 55) received three face-to-face individual PA consultations
Number of subjects: 109
Study 26686681 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 109
Study 24570490 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (n=68)
Number of subjects: 136
Study 24570490 — intervention group
Group type: COMPARATOR
Intervention: Non‐landiolol (control, n=68)
Number of subjects: 136
Study 21484276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotetrabenazine ([(3)H]TBZOH) binding in children with MDD
Number of subjects: 14
Study 21484276 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (N=16)
Number of subjects: 14
Study 18087034 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-focused counseling in all-African-American groups
Number of subjects: 0
Study 18087034 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional counseling in all-African-American groups
Number of subjects: 0
Study 18087034 — intervention group
Group type: COMPARATOR
Intervention: Conventional counseling in racially-mixed groups
Number of subjects: 0
Study 18087034 — intervention group
Group type: COMPARATOR
Intervention: All counseling options
Number of subjects: 0